LIVIVO - Search results -

Search results

Result 1 - 10 of total 22

Search options

Article ; Online: Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2022. Part I.

Maiolino, Angelo / Crusoé, Edvan de Queiroz / Martinez, Gracia Aparecida / Braga, Walter Moisés Tobias / de Farias, Danielle Leão Cordeiro / Bittencourt, Rosane Isabel / Neto, Jorge Vaz Pinto / Ribeiro, Glaciano Nogueira / Bernardo, Wanderley Marques / Tristão, Luca / Magalhaes, Roberto J P / Hungria, Vânia Tietsche de Moraes

Hematology, transfusion and cell therapy

2022 Volume 44, Issue 3, Page(s) 410–418

Language	English
Publishing date	2022-07-20
Publishing country	Brazil
Document type	Journal Article
ISSN	2531-1387
ISSN (online)	2531-1387
DOI	10.1016/j.htct.2022.06.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel - ABHH monoclonal gammopathies committe.

Hungria, Vania / Garnica, Marcia / Crusoé, Edvan de Queiroz / Magalhaes Filho, Roberto Jose Pessoa de / Martinez, Gracia / Bittencourt, Rosane / Farias, Danielle Leão Cordeiro de / Braga, Walter Moises / Neto, Jorge Vaz Pinto / Ribeiro, Glaciano Nogueira / Maiolino, Angelo

Hematology, transfusion and cell therapy

2020 Volume 42, Issue 3, Page(s) 200–205

Abstract: Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access and ... ...

Abstract	Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access and the quality of care in cancer therapy. The COVID-19 pandemic impacts the number of infected, its related mortality, as well as the care of cancer patients. Multiple myeloma patients are a particular group with several important aspects to be considered during pandemic times. In essence, they are immunosuppressed in different intensities during their treatment. Most of them are elderly and all of them require long-term therapy, with prolonged contact with the health care system, possibly including a stem cell transplant during the treatment. A panel of experts in multiple myeloma and infectious diseases discusses pieces of evidence and the lack of the same in the scenario of COVID-19 in myeloma patients, while also exposing what is expected for the next phases of the COVID-19 pandemic.
Keywords	covid19
Language	English
Publishing date	2020-05-13
Publishing country	Brazil
Document type	Journal Article
ISSN	2531-1387
ISSN (online)	2531-1387
DOI	10.1016/j.htct.2020.05.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Managing patients with multiple myeloma during the COVID-19 pandemic

Hematology, Transfusion and Cell Therapy

recommendations from an expert panel – ABHH monoclonal gammopathies committe

2020 Volume 42, Issue 3, Page(s) 200–205

Keywords	covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
ISSN	2531-1379
DOI	10.1016/j.htct.2020.05.001
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Managing patients with multiple myeloma during the COVID-19 pandemic

Hungria, Vania / Garnica, Marcia / Crusoé, Edvan de Queiroz / Magalhaes Filho, Roberto Jose Pessoa de / Martinez, Gracia / Bittencourt, Rosane / Farias, Danielle Leão Cordeiro de / Braga, Walter Moises / Pinto Neto, Jorge Vaz / Ribeiro, Glaciano Nogueira / Maiolino, Angelo

Hematology, Transfusion and Cell Therapy v.42 n.3 2020

recommendations from an expert panel - ABHH monoclonal gammopathies committe

2020

Abstract: ABSTRACT Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the ... ...

Abstract	ABSTRACT Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access and the quality of care in cancer therapy. The COVID-19 pandemic impacts the number of infected, its related mortality, as well as the care of cancer patients. Multiple myeloma patients are a particular group with several important aspects to be considered during pandemic times. In essence, they are immunosuppressed in different intensities during their treatment. Most of them are elderly and all of them require long-term therapy, with prolonged contact with the health care system, possibly including a stem cell transplant during the treatment. A panel of experts in multiple myeloma and infectious diseases discusses pieces of evidence and the lack of the same in the scenario of COVID-19 in myeloma patients, while also exposing what is expected for the next phases of the COVID-19 pandemic.
Keywords	COVID-19 ; SARS-CoV-2 ; Multiple myeloma ; covid19
Subject code	610
Language	English
Publishing date	2020-09-01
Publisher	Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
Publishing country	br
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Managing patients with multiple myeloma during the COVID-19 pandemic

Vania Hungria / Marcia Garnica / Edvan de Queiroz Crusoé / Roberto Jose Pessoa de Magalhaes Filho / Gracia Martinez / Rosane Bittencourt / Danielle Leão Cordeiro de Farias / Walter Moises Braga / Jorge Vaz Pinto Neto / Glaciano Nogueira Ribeiro / Angelo Maiolino

Hematology, Transfusion and Cell Therapy, Vol 42, Iss 3, Pp 200-

recommendations from an expert panel – ABHH monoclonal gammopathies committe

2020 Volume 205

Abstract	Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access and the quality of care in cancer therapy. The COVID-19 pandemic impacts the number of infected, its related mortality, as well as the care of cancer patients. Multiple myeloma patients are a particular group with several important aspects to be considered during pandemic times. In essence, they are immunosuppressed in different intensities during their treatment. Most of them are elderly and all of them require long-term therapy, with prolonged contact with the health care system, possibly including a stem cell transplant during the treatment. A panel of experts in multiple myeloma and infectious diseases discusses pieces of evidence and the lack of the same in the scenario of COVID-19 in myeloma patients, while also exposing what is expected for the next phases of the COVID-19 pandemic.
Keywords	COVID-19 ; SARS-CoV-2 ; Multiple myeloma ; Diseases of the blood and blood-forming organs ; RC633-647.5 ; covid19
Subject code	610
Language	English
Publishing date	2020-07-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Rationale and design of the "Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled" trial (TOCIBRAS).

Farias, Danielle Leão Cordeiro de / Prats, João / Cavalcanti, Alexandre Biasi / Rosa, Regis Goulart / Machado, Flávia Ribeiro / Berwanger, Otávio / Azevedo, Luciano César Pontes de / Lopes, Renato Delascio / Avezum, Álvaro / Kawano-Dourado, Leticia / Damiani, Lucas Petri / Rojas, Salomón Soriano Ordinola / Oliveira, Cleyton Zanardo de / Andrade, Luis Eduardo Coelho / Sandes, Alex Freire / Pintão, Maria Carolina / Castro Júnior, Claudio Galvão de / Scheinberg, Phillip / Veiga, Viviane Cordeiro

Revista Brasileira de terapia intensiva

2020 Volume 32, Issue 3, Page(s) 337–347

Abstract: Introduction: Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients. ... ...

Title translation	Justificativa e delineamento do estudo “Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicêntrico, randomizado, controlado” (TOCIBRAS).
Abstract	Introduction: Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients. We designed a trial testing tocilizumab versus standard of care intending to improve the outcomes by inhibiting interleukin-6, an important inflammatory mediator in COVID-19. Methods and analysis: This open-label multicentre randomized controlled trial will compare clinical outcomes of tocilizumab plus standard of care versus standard of care alone in patients with moderate to severe COVID-19. Two of the following four criteria are required for protocol enrolment: D-dimer > 1,000ng/mL; C reactive protein > 5mg/dL, ferritin > 300mg/dL, and lactate dehydrogenase > upper limit of normal. The primary objective will be to compare the clinical status on day 15, as measured by a 7-point ordinal scale applied in COVID-19 trials worldwide. The primary endpoint will be assessed by an ordinal logistic regression assuming proportional odds ratios adjusted for stratification variables (age and sex). Ethics and dissemination: The TOCIBRAS protocol was approved by local and central (national) ethical committees in Brazil following current national and international guidelines/directives. Each participating center had the study protocol approved by their institutional review boards before initiating protocol enrolment. The data derived from this trial will be published regardless of the results. If proven active, this strategy could alleviate the consequences of the inflammatory response in COVID-19 patients and improve their clinical outcomes.
MeSH term(s)	Humans ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Brazil ; COVID-19 ; Interleukin-6/antagonists & inhibitors ; Pandemics ; Severity of Illness Index ; COVID-19 Drug Treatment/methods ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic
Chemical Substances	Anti-Inflammatory Agents ; Antibodies, Monoclonal, Humanized ; Interleukin-6 ; tocilizumab (I031V2H011)
Keywords	covid19
Language	English
Publishing date	2020-09-29
Publishing country	Brazil
Document type	Clinical Trial Protocol ; Journal Article
ZDB-ID	2732162-9
ISSN	1982-4335 ; 1982-4335
ISSN (online)	1982-4335
ISSN	1982-4335
DOI	10.5935/0103-507X.20200060
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Managing Patients with Multiple Myeloma during the COVID-19 Pandemic: Recommendations from an Expert Panel - ABHH Monoclonal Gammopathies Committe

Hungria, Vania / Garnica, Marcia / de Queiroz Crusoé, Edvan / de Magalhaes Filho, Roberto Jose Pessoa / Martinez, Gracia / Bittencourt, Rosane / de Farias, Danielle Leão Cordeiro / Braga, Walter Moises / Neto, Jorge Vaz Pinto / Ribeiro, Glaciano Nogueira / Maiolino, Angelo

Abstract	Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access and the quality of care in cancer therapy. The COVID-19 pandemic impacts the number of infected, its related mortality, as well as the care of cancer patients. Multiple myeloma patients are a particular group with several important aspects to be considered during pandemic times. In essence, they are immunosuppressed in different intensities during their treatment. Most of them are elderly and all of them require long-term therapy, with prolonged contact with the health care system, possibly including a stem cell transplant during the treatment. A panel of experts in multiple myeloma and infectious diseases discusses pieces of evidence and the lack of the same in the scenario of COVID-19 in myeloma patients, while also exposing what is expected for the next phases of the COVID-19 pandemic.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #245566
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Justificativa e delineamento do estudo “Tocilizumabe em pacientes com COVID-19 moderado a grave

Revista Brasileira de Terapia Intensiva n.ahead 2020

estudo aberto, multicêntrico, randomizado, controlado” (TOCIBRAS)

2020

Abstract: RESUMO Introdução: Os marcadores pró-inflamatórios desempenham papel importante na severidade de pacientes com COVID-19. Assim, terapêuticas anti-inflamatórias são agentes interessantes para potencialmente combater a cascata inflamatória descontrolada em ...

Abstract	RESUMO Introdução: Os marcadores pró-inflamatórios desempenham papel importante na severidade de pacientes com COVID-19. Assim, terapêuticas anti-inflamatórias são agentes interessantes para potencialmente combater a cascata inflamatória descontrolada em tais pacientes. Delineamos um ensaio para testar tocilizumabe em comparação com o tratamento padrão, tendo como objetivo melhorar os desfechos por meio da inibição da interleucina 6, um importante mediador inflamatório na COVID-19. Métodos e análises: Este será um estudo aberto multicêntrico, randomizado e controlado, que comparará os desfechos de pacientes tratados com tocilizumabe mais tratamento padrão com o tratamento padrão isoladamente em pacientes com COVID-19 moderada a grave. Como critérios de inclusão, serão exigidos dois dos quatro critérios a seguir: dosagens de dímero D acima de 1.000ng/mL, proteína C-reativa acima de 5mg/dL, ferritina acima de 300mg/dL e desidrogenase lática acima do limite superior do normal. O objetivo primário será comparar a condição clínica no dia 15, conforme avaliação por meio de escala ordinal de 7 pontos aplicada nos estudos de COVID-19 em todo o mundo. O desfecho primário será avaliado por regressão logística ordinal assumindo razões de propensão proporcionais ajustadas pelas variáveis de estratificação (idade e sexo). Ética e disseminação: O TOCIBRAS foi aprovado pelos comitês de ética locais e central (nacional) do Brasil em conformidade com as atuais diretrizes e orientações nacionais e internacionais. Cada centro participante obteve aprovação do estudo por parte de seu comitê de ética em pesquisa, antes de iniciar as inscrições no protocolo. Os dados derivados deste ensaio serão publicados independentemente de seus resultados. Se tiver sua efetividade comprovada, esta estratégia terapêutica poderá aliviar as consequências da resposta inflamatória na COVID-19 e melhorar os resultados clínicos.
Keywords	Coronavírus ; Tocilizumabe ; Covid-19 ; SARS-COV-2 ; covid19
Language	Portuguese
Publishing date	2020-01-01
Publisher	Associação de Medicina Intensiva Brasileira - AMIB
Publishing country	br
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Justificativa e delineamento do estudo “Tocilizumabe em pacientes com COVID-19 moderado a grave

Revista Brasileira de Terapia Intensiva v.32 n.3 2020

estudo aberto, multicêntrico, randomizado, controlado” (TOCIBRAS)

2020

Abstract	RESUMO Introdução: Os marcadores pró-inflamatórios desempenham papel importante na severidade de pacientes com COVID-19. Assim, terapêuticas anti-inflamatórias são agentes interessantes para potencialmente combater a cascata inflamatória descontrolada em tais pacientes. Delineamos um ensaio para testar tocilizumabe em comparação com o tratamento padrão, tendo como objetivo melhorar os desfechos por meio da inibição da interleucina 6, um importante mediador inflamatório na COVID-19. Métodos e análises: Este será um estudo aberto multicêntrico, randomizado e controlado, que comparará os desfechos de pacientes tratados com tocilizumabe mais tratamento padrão com o tratamento padrão isoladamente em pacientes com COVID-19 moderada a grave. Como critérios de inclusão, serão exigidos dois dos quatro critérios a seguir: dosagens de dímero D acima de 1.000ng/mL, proteína C-reativa acima de 5mg/dL, ferritina acima de 300mg/dL e desidrogenase lática acima do limite superior do normal. O objetivo primário será comparar a condição clínica no dia 15, conforme avaliação por meio de escala ordinal de 7 pontos aplicada nos estudos de COVID-19 em todo o mundo. O desfecho primário será avaliado por regressão logística ordinal assumindo razões de propensão proporcionais ajustadas pelas variáveis de estratificação (idade e sexo). Ética e disseminação: O TOCIBRAS foi aprovado pelos comitês de ética locais e central (nacional) do Brasil em conformidade com as atuais diretrizes e orientações nacionais e internacionais. Cada centro participante obteve aprovação do estudo por parte de seu comitê de ética em pesquisa, antes de iniciar as inscrições no protocolo. Os dados derivados deste ensaio serão publicados independentemente de seus resultados. Se tiver sua efetividade comprovada, esta estratégia terapêutica poderá aliviar as consequências da resposta inflamatória na COVID-19 e melhorar os resultados clínicos.
Keywords	Coronavírus ; Tocilizumabe ; Covid-19 ; SARS-COV-2 ; covid19
Language	Portuguese
Publishing date	2020-09-01
Publisher	Associação de Medicina Intensiva Brasileira - AMIB
Publishing country	br
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.

Rodrigues, Celso Arrais / Gonçalves, Matheus Vescovi / Ikoma, Maura Rosane Valério / Lorand-Metze, Irene / Pereira, André Domingues / Farias, Danielle Leão Cordeiro de / Chauffaille, Maria de Lourdes Lopes Ferrari / Schaffel, Rony / Ribeiro, Eduardo Flávio Oliveira / Rocha, Talita Silveira da / Buccheri, Valeria / Vasconcelos, Yuri / Figueiredo, Vera Lúcia de Piratininga / Chiattone, Carlos Sérgio / Yamamoto, Mihoko

Revista brasileira de hematologia e hemoterapia

2016 Volume 38, Issue 4, Page(s) 346–357

Abstract: Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express ... ...

Abstract	Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19
Language	English
Publishing date	2016-08-20
Publishing country	Brazil
Document type	Journal Article
ZDB-ID	2105177-X
ISSN	1806-0870 ; 1516-8484
ISSN (online)	1806-0870
ISSN	1516-8484
DOI	10.1016/j.bjhh.2016.07.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito